Expression of sex steroid receptor subtypes in normal and malignant breast tissue – a pilot study in postmenopausal women

References

• Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci 1996; 93: 5925–30
   PubMed Web of Science ®Google Scholar
• Gustafsson JA, Warner M. Estrogen receptor beta in the breast, role in estrogen responsiveness and development of breast cancer. J Steroid Biochem Mol Biol 2000; 74: 245–8
   PubMedGoogle Scholar
• Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 2001; 61: 2537–41
   PubMed Web of Science ®Google Scholar
• Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999; 140: 5566–78
   PubMed Web of Science ®Google Scholar
• Leygue E, Dotzlaw H, Watson PH, Murphy LC. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res 1998; 58: 3197–201
   PubMed Web of Science ®Google Scholar
• Conneely OM, Lydon JP, De Mayo F, O'Malley BW. Reproductive functions of the progesterone receptor. J Soc Gynecol Investig 2000; 7: S25–32
   Google Scholar
• Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 2004; 10: 2751–60
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women, the Women's Health Initiative Randomized Trial. JAMA 2003; 289: 3243–53
   PubMed Web of Science ®Google Scholar
• Santen RJ. Risk of breast cancer with progestins, critical assessment of current data. Steroids 2003; 68: 953–64
   PubMed Web of Science ®Google Scholar
• Isaksson E, Wang H, Sahlin L, von Schoultz B, Cline JM, von Schoultz E. Effects of long-term HRT and tamoxifen on the expression of progesterone receptors A and B in breast tissue from surgically postmenopausal cynomolgus macaques. Breast Cancer Res Treat 2003; 79: 233–9
   PubMed Web of Science ®Google Scholar
• Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer, a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004; 13: 1558–68
   PubMed Web of Science ®Google Scholar
• Cheng G, Li Y, Omoto Y, Wang Y, Berg T, Nord M, et al. Differential regulation of estrogen receptor (ER)alpha and ERbeta in primate mammary gland. J Clin Endocrinol Metab 2005; 90: 435–44
   PubMed Web of Science ®Google Scholar
• Löfgren L, Skoog L, von Schoultz E, Tani E, Isaksson E, Fernstad R, et al. Hormone receptor status in breast cancer–a comparison between surgical specimens and fine needle aspiration biopsies. Cytopathology 2003; 14: 136–42
   PubMedGoogle Scholar
• Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474–81
   PubMed Web of Science ®Google Scholar
• Shaw JA, Udokang K, Mosquera JM, Chauhan H, Jones JL, Walker RA. Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. J Pathol 2002; 198: 450–7
   PubMedGoogle Scholar
• Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K, et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 2003; 201: 213–20
   PubMed Web of Science ®Google Scholar
• Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004; 11: 537–51
   PubMed Web of Science ®Google Scholar
• Turgeon JL, McDonnell DP, Martin KA, Wise PM. Hormone therapy, physiological complexity belies therapeutic simplicity. Science 2004; 304: 1269–73
   PubMed Web of Science ®Google Scholar
• Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001; 276: 36869–72
   PubMed Web of Science ®Google Scholar
• Cowley SM, Parker MG. A comparison of transcriptional activation by ER alpha and ER beta. J Steroid Biochem Mol Biol 1999; 69: 165–75
   PubMed Web of Science ®Google Scholar
• Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997; 277: 1508–10
   PubMed Web of Science ®Google Scholar
• Cunha GR, Young P, Hom YK, Cooke PS, Taylor JA, Lubahn DB. Elucidation of a role for stromal steroid hormone receptors in mammary gland growth and development using tissue recombinants. J Mammary Gland Biol Neoplasia 1997; 2: 393–402
   PubMed Web of Science ®Google Scholar
• Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 2002; 277: 5209–18
   PubMed Web of Science ®Google Scholar
• Shyamala G, Yang X, Cardiff RD, Dale E. Impact of progesterone receptor on cell-fate decisions during mammary gland development. Proc Natl Acad Sci 2000; 97: 3044–9
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy, the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–12
   PubMed Web of Science ®Google Scholar
• Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, et al. Adaptive hypersensitivity to estrogen, mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocr Relat Cancer 2003; 10: 111–30
   PubMedGoogle Scholar
• Jarvinen TA, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 2000; 156: 29–35
   PubMed Web of Science ®Google Scholar
• Myers E, Fleming FJ, Crotty TB, Kelly G, McDermott EW, O'Higgins NJ, et al. Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br J Cancer 2004; 91: 1687–93
   PubMedGoogle Scholar
• Omoto Y, Inoue S, Ogawa S. Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett 2001; 163: 207–12
   PubMed Web of Science ®Google Scholar